オンコロジーベースのIn-Vivo CROの世界市場レポート 2025年

オンコロジーベースのIn-Vivo CRO市場規模は、今後数年で急成長が見込まれます。2029年には22億8,000万米ドルに成長し、CAGRは10.9％となります。予測期間の成長は、新たな市場機会、免疫腫瘍学治療へのシフト、腫瘍学臨床試験の増加、精密医療、標的治療によるものと考えられます。予測期間における主な動向には、再生医療と細胞療法、迅速な医薬品開発への需要、デジタル化とデータ分析、腫瘍微小環境への注目、生物製剤と免疫療法の増加などがあります。

がんの罹患率の増加は、将来的に腫瘍学をベースとした生体内医薬品開発業務受託機関（CRO）市場の成長を促進すると予測されます。がんは、異常な細胞が無秩序に分裂し、周囲の組織を侵し、血液やリンパ系を介して体の他の部分に広がる可能性のある疾患群です。効果的ながんの診断と治療には、革新的な医薬品や医療機器が必要であり、市場に出回るまでには、さまざまな前臨床試験、臨床試験、規制プロセスを経る必要があります。オンコロジーin-vivo CROとは、ヒトでの臨床試験に先立ち、前臨床in-vivo試験（動物、植物、全細胞などの生体を用いた試験）に関わるステップの全部または一部を実施することを含む研究サービスを提供するために、スポンサーから契約された企業です。がんの罹患率が上昇を続ける中、革新的な治療や治療法に対する需要も増加しており、がんをベースとしたin-vivo CRO市場の成長を後押ししています。例えば、米国を拠点とする非営利団体である米国がん協会は、2022年に国内で確認されたがん関連の死亡者数は約60万9,000人、新規がん患者数は190万人と報告しています。2024年には、死亡率のわずかな上昇を反映して、推定62万人のがん死亡が予測されています。その結果、がんの有病率の上昇が、腫瘍学ベースの生体内CRO市場の成長を牽引しています。

ヘルスケア支出の増加は、がんベースの体外 CRO市場の拡大を促進すると予想されます。ヘルスケア支出は、ヘルスケアサービスに関連する費用を含み、オンコロジー分野におけるin-vitro CROサービスの開発とアクセシビリティに大きく影響します。カナダ医療情報研究所（Canadian Institute for Health Information）は、2022年のヘルスケア支出が前年比0.8%増の3,310億米ドルになると報告しています。この支出の急増が、がん領域の体外 CRO市場の成長を際立たせています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界オンコロジーベースのIn-Vivo CRO PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のオンコロジーベースのIn-Vivo CRO市場：成長率分析
• 世界のオンコロジーベースのIn-Vivo CRO市場の実績：規模と成長, 2019-2024
• 世界のオンコロジーベースのIn-Vivo CRO市場の予測：規模と成長, 2024-2029, 2034F
• 世界オンコロジーベースのIn-Vivo CRO総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のオンコロジーベースのIn-Vivo CRO市場適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血液がん
• 固形腫瘍
• その他の適応症
• 世界のオンコロジーベースのIn-Vivo CRO市場モデル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 同系モデル
• 異種移植
• 患者由来異種移植（PDX）
• その他のモデル
• 世界のオンコロジーベースのIn-Vivo CRO市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• リハビリテーションセンター
• 世界のオンコロジーベースのIn-Vivo CRO市場血液がんの種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 白血病
• リンパ腫
• 骨髄腫
• 世界のオンコロジーベースのIn-Vivo CRO市場、固形腫瘍の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 乳がん
• 肺がん
• 大腸がん
• 前立腺がん
• その他の固形腫瘍
• 世界のオンコロジーベースのIn-Vivo CRO市場、その他の適応症のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 神経芽細胞腫
• 胚細胞腫瘍
• 肉腫
• その他の具体的な適応症

第7章 地域別・国別分析

• 世界のオンコロジーベースのIn-Vivo CRO市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のオンコロジーベースのIn-Vivo CRO市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• オンコロジーベースのIn-Vivo CRO市場：競合情勢
• オンコロジーベースのIn-Vivo CRO市場：企業プロファイル
  • Crown Bioscience Overview, Products and Services, Strategy and Financial Analysis
  • Charles River Laboratories International Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Taconic Biosciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • The Jackson Laboratory Overview, Products and Services, Strategy and Financial Analysis
  • ICON plc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• WuXi AppTec Inc.
• Eurofins Scientific SE
• Labcorp Drug Development
• Champion Oncology Inc.
• Xentech SAS
• Thermo Fisher Scientific Inc.
• MI Bioresearch Inc.
• Clintec International Private Limited
• Worldwide Clinical Trials Inc.
• Pharm-Olam LLC
• Clinipace Clinical Research Private Limited
• Covance Inc.
• Evotec SE
• Living Tumor Laboratory
• Oncodesign SA

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• オンコロジーベースのIn-Vivo CRO市場2029：新たな機会を提供する国
• オンコロジーベースのIn-Vivo CRO市場2029：新たな機会を提供するセグメント
• オンコロジーベースのIn-Vivo CRO市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

An oncology-focused in-vivo contract research organization (CRO) is a company contracted by another entity to conduct various stages of preclinical in-vivo studies for oncology drugs or devices. This includes designing, overseeing, monitoring, and analyzing preclinical in-vivo research involving living organisms such as animals, plants, or cells.

The primary areas of focus for oncology-based in-vivo CROs encompass blood cancer, solid tumors, and other related indications. Blood cancers originate from tissues responsible for blood formation, such as immune cells and bone marrow, including leukemia, lymphoma, and multiple myeloma. These CROs provide in-vivo testing services utilizing models such as blood cancer-based xenografts and others to expedite drug development research, aiding sponsors of drugs and devices in gaining market approval. Various models, including syngeneic, xenograft, patient-derived xenograft (PDX), and others, are employed by oncology-based in-vivo CROs and applied within hospital and rehabilitation settings.

The oncology based in-vivo CRO software market research report is one of a series of new reports from The Business Research Company that provides oncology based in-vivo CRO software market statistics, including oncology based in-vivo CRO software industry global market size, regional shares, competitors with a oncology based in-vivo CRO software market share, detailed oncology based in-vivo CRO software market segments, market trends and opportunities, and any further data you may need to thrive in the oncology based in-vivo CRO software industry. This oncology based in-vivo CRO software market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oncology based in-vivo cro market size has grown strongly in recent years. It will grow from$1.39 billion in 2024 to $1.5 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to increasing focus on oncology therapeutics, increasing incidence of cancer, shift towards personalized medicine, pharmaceutical industry growth, and demand for target-specific therapies

The oncology based in-vivo cro market size is expected to see rapid growth in the next few years. It will grow to $2.28 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to emerging market opportunities, a shift towards immuno-oncology therapies, a rise in oncology clinical trials, precision medicine, and targeted therapies. Major trends in the forecast period include regenerative medicine and cell therapies, demand for faster drug development, digitalization and data analytics, focus on tumor microenvironment, and rise in biologics and immunotherapies.

The increasing incidence of cancer is projected to drive growth in the oncology-based in-vivo contract research organization (CRO) market in the future. Cancer is characterized by a group of diseases where abnormal cells divide uncontrollably, invade surrounding tissues, and can spread to other parts of the body via the blood and lymphatic systems. Effective cancer diagnosis and treatment necessitate innovative drugs and devices that undergo various preclinical trials, clinical trials, and regulatory processes before they can reach the market. An oncology in-vivo CRO is a company contracted by a sponsor to provide research services, including conducting all or part of the steps involved in preclinical in-vivo studies (testing on living organisms such as animals, plants, or whole cells) prior to human trials. As the prevalence of cancer continues to rise, the demand for innovative treatments and therapies is also increasing, thereby propelling the growth of the oncology-based in-vivo CRO market. For example, the American Cancer Society, a non-profit organization based in the U.S., reported approximately 609,000 cancer-related deaths and 1.9 million new cancer cases identified in the country in 2022. In 2024, an estimated 620,000 cancer deaths are anticipated, reflecting a slight increase in mortality rates. Consequently, the rising prevalence of cancer is driving growth in the oncology-based in-vivo CRO market.

The upsurge in healthcare spending is expected to drive the expansion of the oncology-based in-vitro CRO market. Healthcare expenditure, encompassing costs related to healthcare services, significantly influences the development and accessibility of in-vitro CRO services within the oncology sector. Notably, the Canadian Institute for Health Information reported a rise in healthcare expenditure to $331 billion in 2022, indicating an 0.8% increase from the previous year. This surge in spending accentuates the market's growth within the oncology-based in-vitro CRO domain.

Leading companies in the oncology-based in-vivo CRO market are increasingly focusing on personalized oncology models to establish a competitive edge. These personalized oncology models leverage patient-derived xenografts (PDXs) to develop customized treatment strategies, thereby improving the relevance and effectiveness of preclinical studies. For example, in 2022, Charles River Laboratories, a life sciences company based in the U.S., introduced its OncoMouse platform, which utilizes PDX technology for more precise tumor modeling. This platform offers high-throughput screening capabilities and real-time monitoring of tumor growth, facilitating quick evaluations of therapeutic responses. Furthermore, it includes integrated data analytics to refine treatment protocols according to individual patient profiles. These developments represent a significant shift toward more effective and patient-focused methods in cancer research.

Companies within this market segment are focusing on novel solutions such as CAR T-cell therapies to gain a competitive edge. For instance, Seattle Children's Hospital and Research Institute launched BrainChild Bio in May 2023, targeting CAR T-cell therapies for pediatric brain tumors such as diffuse intrinsic pontine gliomas (DIPG). This platform incorporates synthetic technologies to enhance CAR T-cell therapy for CNS malignancies, aiming to expand its applications to other challenging brain tumors such as glioblastoma and brain metastases. The pursuit of these innovative therapies signifies a strategic move to advance treatment options within the oncology-based in-vivo CRO market.

In March 2023, ClinChoice Medical Development, a US-based contract research organization (CRO) that provides research services to accelerate drug and device approvals, acquired Cromsource S.r.l. for an undisclosed amount. Through this acquisition, ClinChoice Medical Development expands its operational capabilities with additional delivery hubs to complement its existing network in Europe and the US. Data science technology offerings in several areas, including risk-based monitoring and decentralized clinical trials, are expanded through acquisition. Cromsource S.r.l. is an Italy-based contract research organization that provides full-research services to the pharmaceutical, biotechnology, and medical device industries.

Major companies operating in the oncology based in-vivo cro market include Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Clintec International Private Limited, Worldwide Clinical Trials Inc., Pharm-Olam LLC, Clinipace Clinical Research Private Limited, Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, GenScript Biotech Corporation, Shanghai Medicilon Inc., Oncolys BioPharma Inc., Pharmalegacy Laboratories, Oncotest GmbH, Oncovision, Biocytogen LLC, Innovent Biologics Inc.

North America was the largest region in the oncology based in-vivo CRO market in 2024. North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology based in-vivo cro market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the oncology based in-vivo cro market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The oncology-based in-vivo CRO market includes revenues earned by entities by providing preclinical research services such as in-vivo testing via models such as Orthotopic tumor models, tumor passaging, tissue culture models, and others for oncology drugs and devices. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oncology Based In-Vivo CRO Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oncology based in-vivo cro market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oncology based in-vivo cro ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oncology based in-vivo cro market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Indication: Blood Cancer; Solid Tumors; Other Indications
• 2) By Model: Syngeneic Model; Xenograft; Patient Derived Xenograft (PDX); Other Models
• 3) By Application: Hospitals; Rehabilitation Centers
• Subsegments:
• 1) By Blood Cancer: Leukemia; Lymphoma; Myeloma
• 2) By Solid Tumors: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Other Solid Tumors
• 3) By Other Indications: Neuroblastoma; Germ Cell Tumors; Sarcomas; Other Specific Indications
• Companies Mentioned: Crown Bioscience; Charles River Laboratories International Inc.; Taconic Biosciences Inc.; The Jackson Laboratory; ICON plc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oncology Based In-Vivo CRO Market Characteristics

3. Oncology Based In-Vivo CRO Market Trends And Strategies

4. Oncology Based In-Vivo CRO Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Oncology Based In-Vivo CRO Growth Analysis And Strategic Analysis Framework

• 5.1. Global Oncology Based In-Vivo CRO PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Oncology Based In-Vivo CRO Market Growth Rate Analysis
• 5.4. Global Oncology Based In-Vivo CRO Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Oncology Based In-Vivo CRO Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Oncology Based In-Vivo CRO Total Addressable Market (TAM)

6. Oncology Based In-Vivo CRO Market Segmentation

• 6.1. Global Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Cancer
• Solid Tumors
• Other Indications
• 6.2. Global Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Syngeneic Model
• Xenograft
• Patient Derived Xenograft (PDX)
• Other Models
• 6.3. Global Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Rehabilitation Centers
• 6.4. Global Oncology Based In-Vivo CRO Market, Sub-Segmentation Of Blood Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Leukemia
• Lymphoma
• Myeloma
• 6.5. Global Oncology Based In-Vivo CRO Market, Sub-Segmentation Of Solid Tumors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Other Solid Tumors
• 6.6. Global Oncology Based In-Vivo CRO Market, Sub-Segmentation Of Other Indications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Neuroblastoma
• Germ Cell Tumors
• Sarcomas
• Other Specific Indications

7. Oncology Based In-Vivo CRO Market Regional And Country Analysis

• 7.1. Global Oncology Based In-Vivo CRO Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Oncology Based In-Vivo CRO Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oncology Based In-Vivo CRO Market

• 8.1. Asia-Pacific Oncology Based In-Vivo CRO Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oncology Based In-Vivo CRO Market

• 9.1. China Oncology Based In-Vivo CRO Market Overview
• 9.2. China Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oncology Based In-Vivo CRO Market

• 10.1. India Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oncology Based In-Vivo CRO Market

• 11.1. Japan Oncology Based In-Vivo CRO Market Overview
• 11.2. Japan Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oncology Based In-Vivo CRO Market

• 12.1. Australia Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oncology Based In-Vivo CRO Market

• 13.1. Indonesia Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oncology Based In-Vivo CRO Market

• 14.1. South Korea Oncology Based In-Vivo CRO Market Overview
• 14.2. South Korea Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oncology Based In-Vivo CRO Market

• 15.1. Western Europe Oncology Based In-Vivo CRO Market Overview
• 15.2. Western Europe Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oncology Based In-Vivo CRO Market

• 16.1. UK Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oncology Based In-Vivo CRO Market

• 17.1. Germany Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oncology Based In-Vivo CRO Market

• 18.1. France Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oncology Based In-Vivo CRO Market

• 19.1. Italy Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oncology Based In-Vivo CRO Market

• 20.1. Spain Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oncology Based In-Vivo CRO Market

• 21.1. Eastern Europe Oncology Based In-Vivo CRO Market Overview
• 21.2. Eastern Europe Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oncology Based In-Vivo CRO Market

• 22.1. Russia Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oncology Based In-Vivo CRO Market

• 23.1. North America Oncology Based In-Vivo CRO Market Overview
• 23.2. North America Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oncology Based In-Vivo CRO Market

• 24.1. USA Oncology Based In-Vivo CRO Market Overview
• 24.2. USA Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oncology Based In-Vivo CRO Market

• 25.1. Canada Oncology Based In-Vivo CRO Market Overview
• 25.2. Canada Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oncology Based In-Vivo CRO Market

• 26.1. South America Oncology Based In-Vivo CRO Market Overview
• 26.2. South America Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oncology Based In-Vivo CRO Market

• 27.1. Brazil Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oncology Based In-Vivo CRO Market

• 28.1. Middle East Oncology Based In-Vivo CRO Market Overview
• 28.2. Middle East Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oncology Based In-Vivo CRO Market

• 29.1. Africa Oncology Based In-Vivo CRO Market Overview
• 29.2. Africa Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oncology Based In-Vivo CRO Market Competitive Landscape And Company Profiles

• 30.1. Oncology Based In-Vivo CRO Market Competitive Landscape
• 30.2. Oncology Based In-Vivo CRO Market Company Profiles
  • 30.2.1. Crown Bioscience Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Charles River Laboratories International Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Taconic Biosciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. The Jackson Laboratory Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. ICON plc. Overview, Products and Services, Strategy and Financial Analysis

31. Oncology Based In-Vivo CRO Market Other Major And Innovative Companies

• 31.1. WuXi AppTec Inc.
• 31.2. Eurofins Scientific SE
• 31.3. Labcorp Drug Development
• 31.4. Champion Oncology Inc.
• 31.5. Xentech SAS
• 31.6. Thermo Fisher Scientific Inc.
• 31.7. MI Bioresearch Inc.
• 31.8. Clintec International Private Limited
• 31.9. Worldwide Clinical Trials Inc.
• 31.10. Pharm-Olam LLC
• 31.11. Clinipace Clinical Research Private Limited
• 31.12. Covance Inc.
• 31.13. Evotec SE
• 31.14. Living Tumor Laboratory
• 31.15. Oncodesign SA

32. Global Oncology Based In-Vivo CRO Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oncology Based In-Vivo CRO Market

34. Recent Developments In The Oncology Based In-Vivo CRO Market

35. Oncology Based In-Vivo CRO Market High Potential Countries, Segments and Strategies

• 35.1 Oncology Based In-Vivo CRO Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Oncology Based In-Vivo CRO Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Oncology Based In-Vivo CRO Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer